Increasing fear of adverse effects drops intention to vaccinate after the introduction of prophylactic HPV vaccine
暂无分享,去创建一个
Alexandros Sotiriadis | Theodoros Agorastos | T. Agorastos | A. Sotiriadis | Themistoklis Dagklis | T. Dagklis | Vaia Siamanta | Konstantinos Chatzigeorgiou | The LYSISTRATA Study Group | K. Chatzigeorgiou | The Lysistrata Study Group | Vaia Siamanta
[1] P. Sparén,et al. Acceptability of HPV vaccination among young adults aged 18-30 years--a population based survey in Sweden. , 2010, Vaccine.
[2] A. Shefer,et al. Human papillomavirus (HPV) awareness and vaccination initiation among women in the United States, National Immunization Survey-Adult 2007. , 2009, Preventive medicine.
[3] M. Petticrew,et al. Newsprint media representations of the introduction of the HPV vaccination programme for cervical cancer prevention in the UK (2005–2008) , 2010, Social Science & Medicine.
[4] Giannoula D. Bakogianni,et al. HPV vaccine acceptance among female Greek students , 2010, International journal of adolescent medicine and health.
[5] G. Bae,et al. Relationship between intention of novel influenza A (H1N1) vaccination and vaccination coverage rate. , 2010, Vaccine.
[6] G. Krogh,et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up , 2006, British Journal of Cancer.
[7] G. Zimet,et al. Human papillomavirus vaccine uptake, predictors of vaccination, and self-reported barriers to vaccination. , 2009, Journal of women's health.
[8] D. Bernstein,et al. Attitudes about human papillomavirus vaccine in young women , 2003, International journal of STD & AIDS.
[9] S. Jacobsen,et al. Correlates for human papillomavirus vaccination of adolescent girls and young women in a managed care organization. , 2010, American journal of epidemiology.
[10] N. Khardori. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial , 2009 .
[11] S. Garland,et al. Safety of human papillomavirus (HPV) vaccines: a review of the international experience so far. , 2009, Vaccine.
[12] M Arbyn,et al. Worldwide burden of cervical cancer in 2008. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] C. Berry-Cabán,et al. HPV vaccination coverage among adolescents aged 9 to 17 years in a United States military treatment facility , 2009, International journal of adolescent medicine and health.
[14] G. Zimet,et al. Factors That Are Associated With Parental Acceptance of Human Papillomavirus Vaccines: A Randomized Intervention Study of Written Information About HPV , 2006, Pediatrics.
[15] K. Ault. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials , 2007, The Lancet.
[16] J. Peto,et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.
[17] D. Bodurka,et al. Are women ready for the HPV vaccine? , 2006, Gynecologic oncology.
[18] M. Watson,et al. Challenges, lessons learned and results following the implementation of a human papilloma virus school vaccination program in South Australia , 2009, Australian and New Zealand journal of public health.
[19] A. Fleischauer,et al. Intent to receive influenza A (H1N1) 2009 monovalent influenza vaccines - two counties, North Carolina. , 2009 .
[20] K. McCaffery,et al. The domino effect: adolescent girls’ response to human papillomavirus vaccination , 2011, The Medical journal of Australia.
[21] L. Balluz,et al. Interim results: state-specific influenza A (H1N1) 2009 monovalent vaccination coverage - United States, October 2009-January 2010. , 2010, MMWR. Morbidity and mortality weekly report.
[22] T. Weiss,et al. Reasons for non-vaccination against HPV and future vaccination intentions among 19-26 year-old women , 2010, BMC women's health.
[23] J. Löwer. [Two unclear cases of death. Can we still recommend HPV vaccination?]. , 2008, MMW Fortschritte der Medizin.
[24] B. Brumback,et al. Factors associated with initiation and completion of human papillomavirus vaccine series among young women enrolled in Medicaid. , 2010, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.
[25] D. Bernstein,et al. Viral Sexually Transmitted Disease Vaccine Acceptability Among College Students , 2003, Sexually transmitted diseases.
[26] K. Wilson,et al. An analysis of the Human Papilloma Virus vaccine debate on MySpace blogs. , 2010, Vaccine.
[27] M Quinn,et al. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. , 1999, BMJ.
[28] M. Schootman,et al. Geographic disparity, area poverty, and human papillomavirus vaccination. , 2010, American journal of preventive medicine.
[29] D. Hoover,et al. Attitudes of adolescent/young adult women toward human papillomavirus vaccination and clinical trials. , 2000, Health care for women international.
[30] David N Durrheim,et al. Acceptance of pandemic (H1N1) 2009 influenza vaccination by the Australian public , 2010, The Medical journal of Australia.
[31] J. Klosky,et al. Factors influencing familial decision-making regarding human papillomavirus vaccination. , 2010, Journal of pediatric psychology.
[32] P C Prorok,et al. Evaluation of screening programmes for gynaecological cancer. , 1985, British Journal of Cancer.
[33] R. Rouzier,et al. Coverage and compliance of Human Papilloma Virus vaccines in Paris: demonstration of low compliance with non-school-based approaches. , 2010, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.
[34] J. Fielding,et al. Human papillomavirus vaccine among adult women: disparities in awareness and acceptance. , 2010, American journal of preventive medicine.
[35] J. Stryker,et al. The HPV vaccine: a content analysis of online news stories. , 2009, Journal of women's health.
[36] M. Ruffin,et al. Worsening disparities in HPV vaccine utilization among 19-26 year old women. , 2011, Vaccine.
[37] Key W Ords. Attitudes, Intentions, and Perceived Barriers to Human Papillomavirus Vaccination Among Korean High School Girls and Their Mothers , 2011 .